Patrick Truesdell
Plus aucun poste en cours
Fortune : - $ au 31/03/2024
Profil
Patrick Truesdell served as Chief Accounting Officer, VP & Controller at Landos Biopharma, Inc. from 2022 to 2023.
Prior to that, he was Vice President-Finance & Controller at Gemini Therapeutics, Inc. from 2021 to 2022.
Truesdell received a graduate degree from the University of Illinois and undergraduate and MBA degrees from Tippie College of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LANDOS BIOPHARMA, INC.
-.--% | 30/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Anciens postes connus de Patrick Truesdell
| Sociétés | Poste | Fin |
|---|---|---|
| LANDOS BIOPHARMA, INC. | Investor Relations Contact | 10/11/2023 |
| GEMI THER | Comptroller/Controller/Auditor | 01/04/2022 |
Formation de Patrick Truesdell
| University of Illinois | Graduate Degree |
| Tippie College of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LANDOS BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
